In a report released yesterday, Silvan Tuerkcan from Oppenheimer maintained a Buy rating on Crispr Therapeutics AG (CRSP), with a price target of $80.00. The company’s shares closed last Monday at $57.75.
According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of 33.8% and a 52.6% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intellia Therapeutics, and Seattle Genetics.
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $75.38, which is a 30.6% upside from current levels. In a report issued on January 30, Chardan Capital also reiterated a Buy rating on the stock.
The company has a one-year high of $74.00 and a one-year low of $30.53. Currently, Crispr Therapeutics AG has an average volume of 1.19M.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.